{"entity":{"id":"oral-serds","kind":"technology","name":"Oral SERDs","aka":[],"tldr":"Oral drugs that destroy the oestrogen receptor rather than just blocking it, working even when the receptor has mutated to escape older hormone therapies.","summary":"Fulvestrant, the first selective oestrogen receptor degrader, needs monthly injections and has poor bioavailability. Oral SERDs (elacestrant, approved in 2023 for ESR1-mutant advanced breast cancer, followed by imlunestrant, camizestrant, giredestrant and the PROTAC degrader vepdegestrant in late trials) degrade the receptor and keep working against ESR1 mutations that arise after aromatase inhibitors. Trials are moving them earlier, guided by circulating tumour DNA detection of ESR1 mutation.","status":"approved","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["hormonal","targeted-therapy"],"technologies":["endocrine-therapy"],"targets":[],"drugs":["elacestrant","imlunestrant","camizestrant","vepdegestrant","giredestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"principle":"Ligand-like molecules bind the oestrogen receptor and induce a conformation that is ubiquitinated and degraded, removing the receptor even when mutated.","strengths":["Oral","Active against ESR1-mutant disease","ctDNA-guided switching strategies"],"limitations":["Benefit concentrated in ESR1-mutant patients","Nausea and fatigue","Several candidates failed in unselected populations"],"since":2023},"route":"/technologies/oral-serds/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/"},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/"}]}}